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Abstract
Objective. To assess the personalized pain intensity goal (PPIG), the achievement of a personalized pain goal response
(PPGR), and patients’ global impression (PGI) in advanced cancer patients after a comprehensive pain and symptom
management. Design. Prospective, longitudinal Setting. Acute pain relief and palliative/supportive care. Subjects. 689
advanced cancer patients. Methods. Measurement of Edmonton Symptom Assessment Score (ESAS) and personal-
ized pain intensity goal (PPIG) at admission (T0). After a week (T7) personalized pain goal response (PPGR) and
patients’ global impression (PGI) were evaluated. Results. The mean PPIG was 1.33 (SD 1.59). A mean decrease in pain
intensity of  2.09 was required on PPIG to perceive a minimal clinically important difference (MCID). A better improve-
ment corresponded to a mean change of  3.41 points, while a much better improvement corresponded to a mean of
 4.59 points. Patients perceived a MCID (little worse) with a mean increase in pain intensity of 0.25, and a worse with a
mean increase of 2.33 points. Higher pain intensity at T0 and lower pain intensity at T7 were independently related to
PGI. 207 (30.0%) patients achieved PPGR. PPGR was associated with higher PPIG at T0 and T7, and inversely associated
to pain intensity at T0 and T7, and Karnofsky level. Patients with high pain intensity at T0 achieved a favorable PGI,
even when PPIG was not achieved by PPGR. Conclusion. PPIG, PPGR and PGI seem to be relevant for evaluating the
effects of a comprehensive management of pain, assisting decision-making process according to patients’ expecta-
tions. Some factors may be implicated in determining the individual target and the clinical response.
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Introduction
Patients with cancer often experience pain [1]. The preva-
lence of pain in this population has been estimated to be
>75% for those with advanced disease [2]. Cancer pain
is a complex multidimensional phenomenon. Inadequate
pain assessment is one the most relevant barriers to
providing appropriate pain management. Thus, patient-
reported pain and symptom evaluation has been consid-
ered the gold standard to assess clinical response. The
Edmonton Symptom Assessment System (ESAS) is one of
the most common tools used to evaluate both physical
and psychological symptoms. This simple instrument,
which is easy to use and repeatable, is based on a unidi-
mensional numeric rating scale ranging from 0 (no symp-
tom) to 10 (worse possible) for each symptom taken into
consideration [3]. However, this instrument may have
some limitations because patients may individually
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interpret the scale, variably expressing intensity. On the
other hand, the clinical response after initiating a particu-
lar treatment is difficult to assess, as the minimal clini-
cally important difference (MCID) is often not
established. The MCID is considered the smallest amount
of change required to impact a patient’s feeling of im-
provement or deterioration after treatment. The MCID
has been the subject of recent research. Some tools have
been reported as methods to assess MCID, including the
distribution method [4–6] and the use of anchors, such as
the change of intensity categories of well-being [7], the
optimal balance between sensitivity and specificity, and
the magnitude of change in outcome reported by the pa-
tient. The need to evaluate the individual variations in
assessing scales or numbers remains of paramount impor-
tance. Thus, the use of the Patient Global Impression
(PGI) scale has been suggested. This is a validated global
rating-of-change scale to assess patients’ subjective re-
sponse, as it is based on the individual feeling of
improvement or deterioration after receiving a drug [8].
Furthermore, a personalized symptom goal has been re-
cently introduced to tailor pain (Patients’ Pain Intensity
Goal [PPIG]) and symptom management, providing a
simple and individualized “target” score on the ESAS
[9,10]. Therapeutic attempts should try to reach such a
threshold for an intrapatient determination of an
expected response to any treatment. The concept of
Personalized Pain Goal Response (PPGR), which is both
practical and meaningful, represents the achievement of
the expected PPIG, individually determined. Factors asso-
ciated with PPIG and PGI have never been examined.
Studies have assessed these points, even for pain [7,9–12].
However, data were retrospectively examined or per-
formed in an outpatient setting, with variable intervals
for the follow-up. An optimal characterization of PPIG
and a study of factors associated with PPGR and PGI, as
perceived by patients, would help clinicians to maximally
personalize pain management and to evaluate meaningful
changes. This is even more important in a palliative care
unit, the setting where pain and symptom management
can be more rapid and effective because daily assessment,
expertise, and timely therapeutic changes may provide
better control of pain and symptoms in a short period.
This study was performed to characterize the PPIG,
PPGR, and PGI after comprehensive pain management in
advanced cancer patients. The secondary aim was to as-
sess the factors that can influence these outcomes.
Methods
This is a subanalysis of a large international study of ad-
vanced cancer patients performed at admission to five
palliative care units in Italy, Brazil, and Greece [13]. The
ethical committees at all participating centers approved
the study. All participants provided written informed
consent. Participating centers were tertiary care palliative
care units within a comprehensive cancer department.
Participants
A comprehensive pain and symptom assessment was per-
formed by a specialist palliative care physician. Inclusion
criteria were age 18 years and a diagnosis of advanced
cancer. Exclusion criteria were no pain, a short life ex-
pectancy (less than two weeks), cognitive failure (a score
of 13 on the Memorial Delirium Assessment Scale
[MDAS]) [14].
Data Collection
Patients’ characteristics, including age, gender, education
level, and cancer diagnosis, were recorded, as well as ini-
tial Karnofsky performance status.
Symptom intensities included in the ESAS (pain, short-
ness of breath, fatigue, nausea, depression, anxiety, drowsi-
ness, insomnia, appetite, feelings of well-being) were
measured at admission (T0). The same measurements were
performed seven days after starting a comprehensive pallia-
tive care treatment (T7). The comprehensive palliative care
intervention was based on specialized assessment and treat-
ment of symptoms. No strict protocols were given, and
treatments were based on local policy. Researchers
participating in the study were experienced in providing
palliative care. One week was assumed to be an acceptable
time to experience the effects of a clinical intervention.
The ESAS is a self-reported tool assessing the intensity
of most common psychological and physical symptoms; it
uses a numeric rating scale ranging from 0 (no symptom)
to 10 (worst intensity) points to examine symptom inten-
sity over the past 24 hours. It is a valid and reliable tool
for assessing the overall symptom burden and is sensitive
to changes produced by treatment [3]. A screening tool for
history of alcohol dependence (CAGE: cut down, annoy,
guilt, eye-opener) was also used, as a positive CAGE score
(2) has been variably shown to have prognostic value in
opioid management [15].
At T0, patients were asked about their PPIG. The
question was: “At what level would you feel comfort-
able with pain?” using the numeric rating scale used
for ESAS [12]. One week (T7) after starting
comprehensive pain and symptom management tailored
to patients’ needs and local policy, ESAS and PPIG
were measured to evaluate the changes. Patients
achieved the PPGR if their intensity measured at T7
was equal to or less than their expected PPIG. At the
same interval (T7), PGI (improvement or deterioration)
was measured on a scale from þ3 to –3 (much better,
better, a bit better, the same, a little worse, worse, and
much worse, respectively). PGI has been used assess a
clinically significant changes in pain intensity [12,13].
The MCID was calculated by PGI at T7 (a bit better or
a little worse, respectively).
Statistical Analysis
Quantitative and qualitative data, including descriptive
statistics, were analyzed for all items. Continuous data
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were expressed as mean 6SD, unless otherwise specified.
Pearson’s chi-square test and the Fisher exact test, as
needed, were used for frequency analysis. To compare
mean patient characteristic changes and their corre-
sponding SDs, with 95% confidence intervals, the
paired-samples Student t test was used, with I type error
set at 5%. PGI was categorized into three classes: deterio-
ration (PGI  –1), no change (PGI¼ 0), and improve-
ment (PGI 1). The level of pain intensity was
categorized into three classes (mild ¼ 1–3, moderate ¼
4–6, severe ¼ 7–10). Univariate analysis of variance
(ANOVA) was performed to evaluate difference between
patients’ clinical characteristics, and post hoc analysis
with the Bonferroni test was used to determine whether
there were pairwise differences. Multivariate logistic re-
gression analysis was performed on the significant varia-
bles using ANOVA to evaluate the correlation between
patient characteristics (independent variables) and PGI
groups (dependent variables). Pearson correlation analy-
sis was conducted to assess the association between
PPGR and patient clinical variables. Data were analyzed
by IBM SPSS software, version 22 (IBM Corp., Armonk,
NY, USA). All P values were two-sided, and P< 0.05
was considered statistically significant.
Results
From the original study, 689 patients with pain at T0
and complete assessment at T7 were analyzed. The char-
acteristics of these patients are reported in Table 1. The
mean age (SD) was 66.7 (11.8) years, 354 patients
(51.4%) were males, and 396 patients (57.5%) had a
Karnofsky level of 50. The mean Karnofsky level (SD)
was 53.7 (12.9). The mean MDAS value (SD) was 4.2
(3.4). One hundred sixty-four patients (23.8%) had an
MDAS in the range of 7–12 at T0. Twenty-six patients
(3.8%) were CAGE positive.
The mean pain intensity (SD) was 5.98 (2.4) at T0 and
3.36 (2.2) at T7. The mean difference (SD) was 2.62 (2.2)
points, which was statistically significant (P< 0.0005). At
T0, 44.3% of patients reported severe pain intensity (7/
10), whereas only 8.1% of patients reported severe intensity
at T7 (P< 0.0001, chi-square test).
PPIG
The majority of patients (87.5%) indicated a PPIG of 3
as a target. The mean PPIGs at T0 and T7 (SD) were 1.33
(1.59), and 0.91 (1.23), respectively (D–0.42 [1.36]). The
difference was statistically significant (<0.0005). Eighty-
three patients (12%) had a PPIG of 5. A higher PPIG
(>4) was significantly associated with a lower Karnofsky
level (odds ratio [OR] ¼ 0.97, 95% confidence interval
[CI] ¼ 0.95–0.98, P¼ 0.002) and higher pain intensity at
T0 (OR ¼ 1.61, 95% CI ¼ 1.41–1.83, P< 0.0005).
PGI
Five hundred thirty-four patients (77.5% reported an im-
provement in PGI [at least bit better]) (Table 2). Patients
perceived an MCID (a bit better) with a mean decrease in
pain intensity of –2.09. A better improvement corre-
sponded to a mean change of –3.41, whereas a much
better improvement corresponded to a mean change of –
4.59 points on the pain intensity scale. In 143 patients
(20.7%), no changes (no improvement, no deterioration)
were recorded. In a low number of patients, pain inten-
sity worsened. Patients perceived an MCID (a little
worse) with a mean increase in pain intensity of 0.25.
They perceived a worse with a mean increase of 2.33
points.
In the univariate analysis, pain intensity at T0,
MDAS, and PPIG at T0 were related to PGI, categorized
into three classes (no change, improvement, deteriora-
tion) (Table 3). Pain intensity at T7 was inversely corre-
lated with PGI (the lower the pain intensity, the higher
the PGI). In the multiple logistic regression analysis,
higher pain intensity at T0 and lower pain intensity at T7
were independently related to PGI (Table 4).
PPGR
At T7, 207 (30.0%) patients achieved their target (PPIG).
PPGR was correlated with PPIG both at T0 and T7 and
Table 1. Characteristics of patients
Age, mean (SD) [range], y 64.3 (12.5) [18–97]
Gender (M/F), No. (%) 1,558 (56.2)/1,213
(43.8)
Karnofsky mean (SD)
[range]
60.3 (19.6) [10–100]
Primary tumor, No. (%) Lung 756 (27.3)
Gastrointestinal 478 (17.2)
Breast 280 (10.1)
Pancreas 271 (9.8)
Urological 175 (6.3)
Prostate 138 (5.0)
Head-neck 141 (5.1)
Gynecologic 126 (4.5)
Liver 94 (3.4)
Hematological 62 (2.2)
Sarcoma 46 (1.7)
Others 308 (11.1)
Disease, No. (%) Loco-regional 499 (18.0)
Metastatic 2,272 (82.0)
Anticancer treatment,
No. (%)
Disease-oriented 2,067 (74.6)
Palliative Care 585 (21.1)
Place of visit, No. (%) Outpatients 761 (27.5)
Day hospital 297 (10.7)
Home care 502 (18.1)
Hospice 89 (3.2)
Hospital inpatient 1,122 (40.5)
Setting, No. (%) Palliative care 623 (22.5)
Oncology 1,397 (50.4)
Pain therapy 738 (26.6)
Radiotherapy 13 (0.5)
Mean background pain
intensity at T0 (SD)
2.9 (1.8)
Mean opioid doses
(SD), mg/d
81.3 (95.7)
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was inversely correlated to pain intensity recorded at T0
and T7 and a lower Karnofsky level (Table 5).
Patients with higher pain intensity at T0 had a favor-
able PGI (P< 0.0001), even when the target, based on
PPIG response, was not achieved. No significant differen-
ces among categories of pain intensity were found for
PPGR (P> 0.05) (Table 6).
Discussion
This subanalysis of data gathered in an international
multicenter study, which recruited a large number of
patients, provided interesting information to help physi-
cians in personalizing pain management and realizing
how much patients would like to improve their pain and
how effectively physicians can help them achieve their
target. Pain intensity significantly decreased after
comprehensive palliative care treatment.
PPIG
Most patients indicated a PPIG of 3, confirming exist-
ing data from previous studies [16]. Although in these
studies PPIG remained unchanged at undetermined
follow-up visits [9,16,17], in the present study, PPIG de-
creased after one week, as if patients wanted to raise their
expectations once they had an improvement in pain in-
tensity or after achieving their initial target. The long
follow-up period of these studies and the short and acute
period of the present study could explain the differences.
PGI
In most patients PGI for pain was positive, given that
534 patients reported an improvement in pain intensity
after one week of treatment. One week is considered to
be a meaningful time frame to stabilize patients admitted
to a place like a palliative care unit, where efforts to man-
age symptoms are intensive and effective [18]. Patients
perceived an MCID with a decrease in pain intensity of
about 2 points. For perceiving a better improvement,
patients required a decrease in pain intensity of about
3.5. A much better improvement was perceived with a
mean decrease of 4.5 points. In previous studies, a lower
Table 2.Minimal clinical difference according to Patient Global Impression after comprehensive pain management
PGI
ESAS Change Score Much Better Better A Bit Better The Same A Little Worse Worse Much Worse
Pain No. 147 162 225 143 8 3 1
Mean (SD) –4.59 (2.01) –3.41 (1.86) –2.09 (1.33) –0.84 (1.84) 0.25 (1.75) 2.33 (0.58) 0.0
ESAS ¼ Edmonton Symptom Assessment System; PGI ¼ Patient’s Global Impression.
Table 3. ANOVA analysis
PGI
PNo Change Improvement Deterioration
Variables No. 143 534 12
Age, y Mean (SD) 67.3 (12.1) 66.5 (11.9) 68.2 (7.4) 0.693
Karnofsky Mean (SD) 55.6 (12.9) 53.2 (12.9) 54.2 (13.1) 0.137
Pain T0 Mean (SD) 4.6 (2.7) 6.4 (2.1) 4.3 (2.1) <0.0005
1 vs 0
1 vs 2
Pain T7 Mean (SD) 3.8 (2.9) 3.2 (1.9) 5.1 (1.9) 0.001
1 vs 0
1 vs 2
MDAS Mean (SD) 3.8 (3.2) 4.4 (3.4) 2.1 (2.6) 0.007
1 vs 2
Patient goal T0 Mean (SD) 0.7 (1.2) 1.5 (1.7) 0.8 (1.1) <0.0005
1 vs 0
Patient goal T7 Mean (SD) 0.7 (1.1) 0.9 (1.3) 1.0 (1.2) 0.061
Patient Global Impression was categorized into three classes: no change (PGI¼ 0), improvement (PGI 1), deterioration (PGI 1).
ANOVA ¼ analysis of variance; MDAS ¼ Memorial Delirium Assessment Scale; PGI ¼ Patient Global Impression.
Table 4. Patient Global Impression
PGI OR 95% CI P
No change PAIN T0 2.177 1.310–3.619 0.003
PAIN T7 0.437 0.270–0.706 0.001
MDAS 1.227 0.955–1.577 0.109
Patient pain goal T0 0.925 0.536–1.595 0.778
Improvement PAIN T0 4.736 2.800–8.011 <0.0005
PAIN T7 0.217 0.132–0.356 <0.0005
MDAS 1.260 0.978–1.622 0.074
Patient pain goal T0 1.259 0.728–2.178 0.409
Multiple logistic regression in reference to PGI category of deterioration.
CI ¼ confidence interval; MDAS ¼ Memorial Delirium Assessment Scale;
OR ¼ odds ratio; PGI ¼ Patient Global Impression.
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MCID was found [7,12]. The retrospective nature of de-
sign, the longer and not constant intervals among obser-
vations, the use of different categories anchored to the
well-being scale [11], or the setting (radiotherapy, outpa-
tients), may explain the differences. Some studies have
reported more relevant changes of pain intensity to per-
ceive a meaningful clinical benefit, including a 33% de-
crease or a reduction of two or more points [19,20],
confirming data found in this study.
The factors principally related to improvement in PGI
have never been assessed. In this study, the higher the
pain intensity, the better the PGI, although not all
patients were able to achieve their target. It is likely that
a more evident feeling of improvement perceived by
patients when they perceive a net decrease in pain inten-
sity (about halving the pain intensity with about 2.5
points of difference) explains this finding. Similarly,
higher PPIG was also independently associated with a
positive PGI, possibly because the level expectation is
easier to be reached with just a little change in pain inten-
sity. Thus, patients who accept a higher level of pain
intensity are more likely to achieve better satisfaction.
Eighty-three patients (12%) had higher values of PPIG at
admission. These patients are likely to require only mini-
mal changes in pain intensity for a positive PGI. On the
other hand, a low level of pain intensity at T7 was associ-
ated with a better PGI, as a consequence of adequate
pain management.
In some studies, initial pain intensity has been found
to be a negative factor for pain prognosis [16,21–23].
These studies, however, clearly showed that clinical
undertreatment was responsible for the outcome. In fact,
patients were stabilized for a very long time (one to three
weeks), suggesting a nonoptimized method for opioid
dose titration. In other circumstances, a retrospective
long follow-up in outpatients (three weeks), based on
only one therapeutic intervention, would have biased the
outcome. Indeed, pain intensity is a dynamic concept,
depending on the moment in which the patient is inter-
cepted [18]. Several surveys and also daily practice sug-
gest that pain control is commonly achieved in a few
days in the majority of patients by using personalized
opioid dose titration [24–30]. Data from this study con-
firm that the higher the level of initial pain intensity, the
better the patient satisfaction score after proper pain
management.
PPGR
Thirty percent of patients achieved their target (PPIG) af-
ter proper pain management. This percentage was lower
than that of patients with a positive PGI. In patients with
higher pain intensity or a lower Karnofsky level, PPGR
was more likely to be achieved, allowing the patient to
reach the level of PPIG expected. Thus, a higher PPIG
allowed the achievement of a better PPGR, as small
improvements were sufficient to obtain the target level
desired by patients. This finding reflects the features of
PGI. Patients with higher pain intensity may have lower
expectations when rating their PPGI scores as high,
which means that active pain management may have a
greater opportunity to achieve PPGR. Patients with a
lower Karnofsky status may have a more positive impres-
sion after palliative care treatment or may merely have
lower expectations. This observation deserves further
study.
This study has some limitations. In comparison
with previous trials examining issues regarding clinical
changes as perceived by patients and PPIG, data were
obtained from patients recruited in palliative care
units, where it is likely that symptom assessment and
treatments are more intensive. Thus, these data are
not generalizable to outpatients or home care settings.
A PPIG scale was used to test MCID in this study.
That is the way patients may individually perceive
clinical change. This tool proved to be repeatable and
easy to understand, even though it lacks other external
criteria.
Table 5. Factors correlated with Patient Pain Goal Response
Patient Pain Goal Response
Age Pearson correlation 0.028
P (2-tailed) 0.460
No. 686
Gender Pearson correlation –0.024
P (2-tailed) 0.527
No. 686
Karnofsky Pearson correlation –0.151**
P (2-tailed) <0.0005
No. 683
Pain T0 Pearson correlation –0.272**
P (2-tailed) <0.0005
No. 686
Patient pain goal T0 Pearson correlation 0.508**
P (2-tailed) <0.0005
No. 686
Pain T7 Pearson correlation –0.778**
P (2-tailed) <0.0005
No. 686
Patient pain goal T7 Pearson correlation 0.115**
P (2-tailed) 0.003
No. 686
Table 6. Patient Pain Goal Response and Patient Global
Impression, according to the categories of pain intensity mea-
sured at T0
Mild,
No. (%)
Moderate,
No. (%)
Severe,
No. (%) Total
Pain T0 127 257 305 689
PPGR (1) 42 (33.1) 77 (30.0) 85 (27.9) 204
PGI (1) 53 (41.7) 215 (83.6)* 266 (87.2)* 534
PGI ¼ Patient Global Impression; PPGR ¼ Patient Pain Goal Response.
*P< 0.0001 in respect to mild pain intensity.
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Conclusions
The PPIG allows clinicians to individualize patient care
and ensures intrapatient determination of a practical and
meaningful pain response. The PPIG, PGI, and PPGR are
measurements that are relevant to the assessment and
decision-making process, according to patients’ expecta-
tions. Some factors, such as pain intensity, PPIG, and
Karnofsky, may influence clinical response, assessed by
PGI and PPGR. Further studies should investigate these
aspects in other palliative care settings.
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